



## **Ocugen Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017**

August 28, 2017

MALVERN, Pa., Aug. 28, 2017 /PRNewswire/ -- Ocugen, Inc. today announced it will be featured as a presenting company at the 19<sup>th</sup> Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City.

Shankar Musunuri, Ph.D., Chairman, CEO and Co-Founder of Ocugen, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link ([www.rodmanevents.com](http://www.rodmanevents.com)) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

The presentation will be webcast live. To access the webcast, please visit [www.rodmanevents.com](http://www.rodmanevents.com). The webcast replay will remain available for 90 days following the live presentation.

### **About Ocugen, Inc.**

Ocugen is a clinical stage biopharmaceutical company focused on developing first-in-class therapeutics to address significant unmet medical needs of patients with eye diseases, including several rare diseases. Our programs are focused on activating novel biologic pathways to treat inflammatory, degenerative, and neovascular diseases of the eye. OCU300 has received first and only Orphan Drug Designation (ODD) from the FDA for the treatment of ocular graft versus host disease (oGVHD). OCU310, a combination product, is currently going through a proof-of-concept clinical study, under an IND, targeting dry eye disease. Both OCU300 and OCU310 are being developed through the FDA's 505(b)(2) pathway and expected to enter into pivotal clinical trials for registration in 2018. OCU100 is a recombinant N-terminal fragment of Lens Epithelium Derived Growth Factor (LEDGF) and is being developed as an orphan indication for the treatment of Retinitis Pigmentosa (RP). OCU200, is an anti-angiogenic tumstatin fusion protein being developed for treatment of wet age-related macular degeneration (AMD). For more information visit [www.ocugen.com](http://www.ocugen.com).

### **Investor Relations:**

Kelly Morello

[kelly.morello@ocugen.com](mailto:kelly.morello@ocugen.com)

+1 484-328-4698

SOURCE Ocugen, Inc.